Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8477000 | 0.76 | CYP3A4 (0.39) | BCHEACHECYP3A4CYP2D6CYP2C19 | |
| SCHEMBL16596978 | 0.71 | BCHE (0.53) | BCHEACHECYP2D6 | |
| SCHEMBL2067120 | 0.71 | BCHE (0.53) | BCHEACHECYP2D6 | |
| SCHEMBL19427415 | 0.69 | CYP3A4 (0.49) | BCHEACHECYP3A4CYP2D6CYP2C19 | |
| SCHEMBL6545035 | 0.67 | CYP3A4 (0.48) | BCHEACHECYP3A4CYP2D6CYP2C19 | |
| SCHEMBL9441368 | 0.66 | SIGMAR1 (0.52) | — | |
| SCHEMBL9151971 | 0.66 | CYP2D6 (0.61) | BCHEACHECYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11757293 | 0.66 | CYP2D6 (0.61) | BCHEACHECYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11755929 | 0.66 | HSD11B1 (0.46) | BCHEACHECYP3A4CYP2D6CYP2C19 | |
| SCHEMBL11447599 | 0.64 | CYP3A4 (0.46) | BCHEACHECYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242939-B2 | Compositions and methods for the treatment of respiratory disorders | CELLIX BIO PRIVATE LIMITED (IN) | 2016-01-26 | — | — | US | disclosed |
| US-20150087670-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | CELLIX BIO PRIVATE LIMITED (IN) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087670-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS | HLA-DRB1, TRPV1, NDUFB11 | BCHE 2349/4885ACHE 417/4885CYP3A4 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.